Very Brief Exposure: Development of a Novel Exposure Modality for Social Anxiety Disorder in Transition-Age Youth
Children's Hospital Los Angeles · with National Institute of Mental Health (NIMH) · NCT06526260
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 16–22 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 80
- US sites recruiting
- 1
- Study start
- August 14, 2024
- Record last updated
- October 19, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The goal of this clinical trial is to identify the circuit activations by very brief exposure (VBE) among youth with social anxiety disorder (SAD) in order to develop a novel intervention for those with SAD. The secondary objectives of this study are to measure the effect of VBE on subjective fear ratings, and participants' awareness and tolerance of the exposure stimuli.
- The primary outcome of this study is the mean activation of frontostriatal and prefrontal brain regions to facial stimuli, as measured by Blood Oxygen Level Dependent (BOLD) response, in 4 regions of interest during the magnetic resonance imaging (MRI).
- Another primary outcome of the study is to identify networks of regions subserving emotion regulation and attention, as measured by BOLD response of corresponding brain regions.
Secondary Outcomes
-The secondary outcome of this study is the fear induced by exposure to facial expression stimuli as measured by a 4-point fear scale during the functional magnetic resonance imaging (fMRI) after each block of 10 facial expression stimuli trials.
Participants will participate in an interview where they will answer questions both inside and outside of the MRI scan. Participants will be asked to rate on a scale the imagines they see while undergoing MRI scan.
Being studied: Very Brief Exposure to Facial Expressions
Conditions: Social Anxiety Disorder
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Patient Population
- Males and females aged 16-22. This age range corresponds with our prior studies of very brief exposure (VBE) in Specific Phobia and will include older adolescents while minimizing potential developmental effects on circuit activation.
- Youth with a Diagnostic and Statistical Manual of Mental Disorders (DSM-5) diagnosis of Social Anxiety Disorder (SAD) on Kiddie Schedule for Affective Disorders and Schizophrenia for School-Aged Children, Computerized version (K-SADS-COMP) for youth ages 16-17, or the computerized version of Structured Clinical Interview for the DSM-5 (NetSCID) for youth ages 18+.
- Healthy Population
- Male and female youth aged 16-22.
- Parents • Parent/caregiver of all ages, no restrictions who are fluent in either English or Spanish.
Exclusion Criteria
- Patient Population
- Primary language other than English or Spanish.
- Active suicidality on the Colombia-Suicide Severity Scale (plan, intent, or behavior)
- Ferromagnetic implants (e.g., pacemaker), metal braces, retainers, tattoos or permanent make-up with metallic content, transdermal medicinal patches that cannot be removed.
- Current psychoactive medication.
- Lifetime diagnosis of: obsessive-compulsive disorder (OCD), psychotic, bipolar, autism spectrum disorder, intellectual disability on the KSADS-COMP or NetSCID.
- Any serious neurological or medical conditions (e.g., Lupus, cancer, human immunodeficiency virus positive (HIV+)) as reported by potential participants.
- Current Post-Traumatic Stress Disorder (PTSD) diagnosis.
- Current severe substance abuse (except tobacco/nicotine).
- Pregnancy, as determined by the participant's self-report prior to the magnetic resonance imaging (MRI) scan.
- Healthy Population
- Primary language other than English or Spanish.
- Lifetime disorders: any anxiety disorders, OCD, psychotic, bipolar, autism spectrum disorder, intellectual disability; any psychiatric disorder in the past 2 years
- Current depression disorder.
- Active psychiatric disorder in the past 2 years.
- Serious neurological or medical conditions.
- Current psychoactive medication.
- Ferromagnetic implants (e.g., pacemaker), metal braces, retainers, tattoos or permanent make-up with metallic content, transdermal medicinal patches that cannot be removed.
- Active suicidality on the Colombia-Suicide Severity Scale (plan, intent, or behavior).
- Pregnancy, as determined by the participant's self-report prior to the MRI scan.
- Parents • Primary language other than English or Spanish.
Recruiting US locations
Children's Hospital Los Angeles
Los Angeles, CA 90027
Site contact: Courtney Marcelino · 3233616456 · cmarcelino@chla.usc.edu
Study contacts (from the official record)
- Courtney Marcelino · 323-361-6456 · cmarcelino@chla.usc.edu
- Bradley S Peterson, MD · 323-361-3654 · bpeterson@chla.usc.edu
Similar studies in California
All mental health studies in California →- RecruitingHealthy volunteersEarly Phase 1
Single and Multiple Ascending Doses of NTX-253 in Healthy Participants and Participants With Stable Schizophrenia
Neurosterix
- Location
- Los Alamitos, CA
- Eligibility basics
- Ages 18–55
- RecruitingPhase 1Overnight stay mentioned
A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia
Leal Therapeutics, Inc
- Location
- Los Alamitos, CA + 9 other US sites
- Eligibility basics
- Ages 18–55
- RecruitingPhase 1Overnight stay mentioned
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
BioXcel Therapeutics Inc
- Location
- Anaheim, CA + 3 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingHealthy volunteersPhase 1
Inflammatory Challenge and Fear
University of California, San Francisco
- Location
- San Francisco, CA
- Eligibility basics
- Ages 18–65